Interested? Do you feel you will benefit?

All Rights Reserved. marcus evans ® 2019

13th Annual Pharma Resource Planning & Portfolio Management 

Prioritizing Projects with Tools, Data, and Governance to Maximize ROI 

February 5-6, 2020
Philadelphia, PA

marcus evans Noth America

What our delegates think of us:

An interview with Kerstin Laudemann, Director of Portfolio Review and Governance at Takeda Pharmaceuticals 

Ahead of the 13th Annual Pharma Resource Planning & Portfolio Management Conference, we spoke with Kerstin Laudemann, Director of Portfolio Review and Governance at Takeda Pharmaceuticals. At Takeda, Kerstin is responsible for driving the portfolio review through the Portfolio Review Committee , which is one of the 4 major decision-making bodies within Takeda, to ensure consistent, high quality decision dialogue with R&D and commercial leadership for both internal and external pipeline opportunities. Kerstin has over 20 years of experience in the Biopharma industry, primarily in the field of Program and Portfolio Management for companies such as Baxter Healthcare, Baxalta and Shire Pharmaceuticals. She has a master’s degree of Science from the Christian-Albrecht’s University Kiel, Germany, and is PMP certified from the Project Management Institute.

You will be presenting on “Examining Critical Governance Expectations to Continue Development on an Asset,” what are some key takeaways the attendees can expect from your session?

This presentation will discuss how to set up an agile governance process, navigating external pressures such as budget, capacity restrictions, while providing the appropriate rigor of risk analysis, value and tradeoff opportunities

Why is it important to integrate an internal governance structure?

As the governance committee is responsible for ensuring that the portfolio is optimized to achieve the organizations strategic objectives, it is imperative that the governance structure is set up in a way that it can oversee all assets - from the earliest stages through LCM activities. 

That set up provides optimal conditions to make portfolio decisions with an enterprise view in mind.

Setting up the right internal governance structure ensures that the right decisions are made, through an integrated team spanning all aspects of drug development - from early research expertise to market access and commercialization. 

What key drivers motivated you to participate at this particular conference? What is the one factor you hope to gain from this forum?

Getting thought leaders together from the field of portfolio and resource management peaked my interest. 

The one factor I am hoping to gain from this forum is further insights into portfolio and resource management from some of the best pharmaceutical companies.

Kerstin is one of our Keynote Speakers:

Why you should attend this marcus evans conference?

Practical insights from active practitioners in your sector

Samantha O’Connor
Executive Director, Head of Operations and Portfolio Management, Centers for Therapeutic Innovation (CTI)
Pfizer Inc.

Jared Fantasia
Director, Global Program Management
Johnson & Johnson

Christopher O’Donovan
Director, Resource Management
Bristol-Myers Squibb

Sean Keck-Mulligan
Director Global Program Management – Workforce Planning
Novartis

Case study: 
Examining Critical Governance Expectations to Continue Development on an Asset

•Identifying the decision points to effectively drive portfolio governance
•Highlighting the benefits of integrating an internal governance structure
•Comparing and contrasting what it means for small vs. large companies to streamline governance processes
•Investigating the various ways to accelerate approvals to reduce timelines

For registration pricing and multiple attendee discounts, please contact:

Jeremy Wise
Jeremywi@marcusevansch.com